These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35834099)

  • 1. VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas.
    Zhou J; Wang J; Kong W; Zhang J; Wu X; Huang J; Zheng J; Chen Y; Zhai W; Xue W
    Cell Oncol (Dordr); 2022 Aug; 45(4):677-687. PubMed ID: 35834099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.
    Verbiest A; Lambrechts D; Van Brussel T; Couchy G; Wozniak A; Méjean A; Lerut E; Oudard S; Verkarre V; Job S; de Reynies A; Machiels JP; Patard JJ; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2018 Aug; 16(4):266-273. PubMed ID: 29503246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
    Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.
    Stenehjem DD; Hahn AW; Gill DM; Albertson D; Gowrishankar B; Merriman J; Agarwal AM; Thodima V; Harrington EB; Au TH; Maughan BL; Houldsworth J; Pal SK; Agarwal N
    PLoS One; 2019; 14(1):e0210415. PubMed ID: 30682039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
    Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
    Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
    Song Y; Huang J; Shan L; Zhang HT
    Chin Med J (Engl); 2015 Aug; 128(15):2026-33. PubMed ID: 26228213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
    Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
    Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
    Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
    Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.
    Del Re M; Crucitta S; Paolieri F; Cucchiara F; Verzoni E; Bloise F; Ciampi R; Mercinelli C; Capuano A; Sportiello L; Martinetti A; Procopio G; Galli L; Porta C; Bracarda S; Danesi R
    J Transl Med; 2022 Aug; 20(1):371. PubMed ID: 35974365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
    Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs.
    Beuselinck B; Jean-Baptiste J; Couchy G; Job S; De Reynies A; Wolter P; Théodore C; Gravis G; Rousseau B; Albiges L; Joniau S; Verkarre V; Lerut E; Patard JJ; Schöffski P; Méjean A; Elaidi R; Oudard S; Zucman-Rossi J
    Br J Cancer; 2015 Nov; 113(9):1313-22. PubMed ID: 26528707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
    Golshayan AR; Brick AJ; Choueiri TK
    Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.
    Kim BJ; Kim JH; Kim HS; Zang DY
    Oncotarget; 2017 Feb; 8(8):13979-13985. PubMed ID: 28103578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.
    Brieger J; Weidt EJ; Schirmacher P; Störkel S; Huber C; Decker HJ
    J Mol Med (Berl); 1999 Jun; 77(6):505-10. PubMed ID: 10475065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.